Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Carl Zeiss focuses on next generation of High Content Analyses tools

Carl Zeiss MicroImaging : 03 December, 2007  (New Product)
Carl Zeiss MicroImaging has launched ASSAYbuilder, a suite of next generation High Content Analyses (HCA) tools, that enables the delivery of high content analyses to research microscopes.
ASSAYbuilder can be added to any Microscope with a digital imaging package including AxioVision.

For the first time, any researcher can upgrade their Zeiss Microscope to an HCA system at a fraction of the price of existing high content screening systems.

High content screening has accelerated drug discovery in the pharmaceutical industry for years. Leveraging the power of research microcopy for high content analyses promises to enable precise Assay development and hit qualification for the screening community while reducing the cost of access for academics that need greater flexibility when imaging and analysing biological targets.

“We are excited about pairing High Content Analyses with high resolution imaging, confocal microscopy, and advanced digital imaging modalities” stated Martin L Pietila, associate product manager for High Content Analysis at Carl Zeiss.

“Bridging research Microscopy and screening constitutes a continuum of technology in the biomedical imaging market. By leveraging our experience with the Thermo Scientific Cellomics product line we have matched the best in class imaging with the best in class high content analysis technology” stated James A Sharp, president and chief executive officer of Carl Zeiss MicroImaging.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo